Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.79M | 13.25M | 14.54M | 13.46M | 10.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.79M | 13.25M | 14.54M | 13.46M | 10.70M |
| Cost of Revenue | 67.54M | 52.39M | 54.13M | 53.03M | 44.12M |
| Gross Profit | -56.76M | -39.14M | -39.59M | -39.57M | -33.42M |
| SG&A Expenses | 36.58M | 30.62M | 29.11M | 28.08M | 30.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.13M | 83.01M | 83.24M | 81.10M | 74.62M |
| Operating Income | -93.34M | -69.76M | -68.70M | -67.64M | -63.92M |
| Income Before Tax | -88.61M | -64.65M | -69.42M | -67.81M | -64.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.61M | -64.65M | -69.42M | -67.81M | -64.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.61M | -64.65M | -69.42M | -67.81M | -64.05M |
| EBIT | -93.34M | -69.76M | -68.70M | -67.64M | -63.92M |
| EBITDA | -92.06M | -68.51M | -67.63M | -66.62M | -62.94M |
| EPS Basic | -0.40 | -0.29 | -0.38 | -0.39 | -0.38 |
| Normalized Basic EPS | -0.25 | -0.18 | -0.24 | -0.25 | -0.24 |
| EPS Diluted | -0.40 | -0.29 | -0.38 | -0.39 | -0.38 |
| Normalized Diluted EPS | -0.25 | -0.18 | -0.24 | -0.25 | -0.24 |
| Average Basic Shares Outstanding | 224.10M | 222.92M | 183.92M | 172.59M | 169.40M |
| Average Diluted Shares Outstanding | 224.10M | 222.92M | 183.92M | 172.59M | 169.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |